1. Market Research
  2. > Pathology
88 reports for Lymphoma (page 1)

Purchase Reports From Reputable Market Research Publishers

Global Bruton’s Tyrosine Kinase (BTK) Inhibitors Market: Size & Forecast with Impact Analysis of COVID-19 (2020-2024)

  • $ 900
  • June 2020
  • 82 pages

B-cell lymphomas can be categorized into aggressive NHL, such as diffuse large B-Cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and burkitt' s lymphoma (BL), and indolent NHL, such as chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma

  • Autoimmune Disease
  • Lymphoma
  • Therapy
  • World
  • AbbVie Inc.

NHL: Mantle cell lymphoma

  • $ 5000
  • April 2016
  • 214 pages

Lymphoma Association (2016) Mantle cell lymphoma.

  • Immunotherapy
  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • AbbVie Inc.

Chronic Lymphocytic Leukemia - Competitive Landscape to 2030

  • $ 3495
  • May 2020
  • 55 pages

Lung Cancer Breast Cancer Leukemia Lymphoma Non-Small Cell Lung...

  • Leukemia
  • Lymphoma
  • AbbVie Inc.
  • AstraZeneca PLC
  • Roche Group

Global Biologics Market: Size, Trends & Forecast (2019-2023 Edition)

  • $ 1200
  • December 2019
  • 97 pages

Enbrel ##. ## Rheumatoid arthritis Amgen, Pfizer Herceptin ##. ## Breast and gastric cancer Roche (Genentech) Avastin ##. ## Various cancers Roche (Genentech) Rituxin ##. ## Lymphoma, Rheumatoid arthritis Roche (Genentech), Biogen Eylea ##. ## Macular degeneration/ edema, retinopathy Bayer, Regeneron

  • Lymphoma
  • Medical Biotechnology
  • Pharmaceutical
  • World
  • AbbVie Inc.

Multiple Myeloma: Global Drug Forecast and Market Analysis to 2027

  • $ 10995
  • March 2019
  • 164 pages

THE LEUKEMIA AND LYMPHOMA SOCIETY (2015) MYELOMA.

  • Cancer
  • Cancer Hormonal Therapy
  • Lymphoma
  • Therapy
  • AbbVie Inc.

Global CML Market Report - 2022

  • $ 3849
  • June 2018
  • 82 pages

Imatinib mesylate is licensed as a firstline treatment for adults with chronic-phase Ph+ CML, and for the management of GIST, and as salvage therapy for Ph+ acute lymphoblastic lymphoma.

  • Lymphoma
  • Therapy
  • AbbVie Inc.
  • Incyte Corporation
  • Merck & Co., Inc.

Ulcerative Colitis: Global Drug Forecast and Market Analysis to 2026

  • $ 10995
  • June 2018
  • 272 pages

THEY COULD ALSO BE AT A HIGHER RISK OF DEVELOPING SHINGLES AND AN INCREASE OF LYMPHOMA AND CANCERS.

  • Hospital
  • Lymphoma
  • Medical Biotechnology
  • Therapy
  • AbbVie Inc.

Biopharmaceuticals Market - Growth, Trends, and Forecast (2019 - 2024)

  • $ 5000
  • August 2019
  • 178 pages

According to the Leukemia and Lymphoma Society (LLS), United States, an estimated combined total of ##, ## people in the United States are expected to be diagnosed with leukemia, lymphoma, or myeloma in 2019.

  • Biopharmaceutical
  • Lymphoma
  • Medical Biotechnology
  • United States
  • AbbVie Inc.

Global Biologics Market: Size, Trends & Forecast (2018-2022)

  • $ 900
  • February 2018
  • 91 pages

Global Biologics Market: Size, Trends & Forecasts (2018-2022) February 2018 ##.

  • Biotech Services
  • Lymphoma
  • Medical Biotechnology
  • World
  • AbbVie Inc.

Global Orphan and Rare Dermatology Drugs Market to 2024 - An Increasingly Competitive Landscape as New Companies Enter the Market with Novel Products, Driving Strong Market Growth

  • $ 4995
  • September 2018
  • 141 pages

However, Humira is packaged with a boxed warning relating to an increased risk of severe infections, such as tuberculosis and bacterial sepsis, and an increased risk of malignancy, such as lymphomas, for patients taking this drug.

  • Autoimmune Disease
  • Dermatological Condition
  • Dermatological Treatment
  • Lymphoma
  • AbbVie Inc.

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - US

  • $ 1995
  • October 2018
  • 169 pages

In June 2018, the FDA approved usage of VENCLEXTA in combination with rituximab for the treatment of people suffering with small lymphocytic lymphoma (SLL) or chronic lymphocytic leukemia (CLL).

  • Lymphoma
  • Medical Equipment
  • Pharmaceutical
  • United States
  • AbbVie Inc.

Global Injectable Drugs Market 2017-2021

  • $ 2500
  • July 2017
  • 84 pages

In January 2017, the FDA approved IMBRUVICA as the first treatment for relapsed/ refractory marginal zone lymphoma.

  • Lymphoma
  • Pathology
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc

Uveitis Therapeutics in Asia-Pacific Markets to 2023 - Increasing Prevalence, Continued Uptake of Biologics and Novel Pipeline Drugs to Drive the Market

  • $ 4995
  • February 2018
  • 91 pages

Further correlations of an increased risk of malignancies were also identified for non-melanoma skin cancer, as well as for lymphoma and leukemia.

  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Market Size
  • AbbVie Inc.

Glioblastoma Multiforme (GBM): Opportunity Analysis and Forecasts to 2027

  • $ 10995
  • October 2018
  • 124 pages

Glioblastoma Multiforme (GBM): Opportunity Analysis and Forecasts to 2027 Summary The Glioblastoma Multiforme (GBM) market is expected to grow from $662.0m in 2017 to $1.4bn in 2027 across the eight majo ...

  • Brain Cancer
  • Lymphoma
  • Therapy
  • United States
  • AbbVie Inc.

Biotechnology - Thematic Research

  • $ 1950
  • September 2018
  • 24 pages

The FDA approved two CAR-T cell therapies in 2017: Novartis' Kymriah for acute lymphoblastic leukemia (ALL); and Gilead Sciences' Yescarta for advanced B-cell lymphoma.

  • Immunotherapy
  • Lymphoma
  • United States
  • AbbVie Inc.
  • Amgen Inc.

The World Market for Cancer Therapeutics by Product

  • $ 4200
  • November 2015
  • 320 pages

Follicular lymphoma tends to be indolent and diffuse lymphoma tends to be aggressive.

  • Cancer
  • Lymphoma
  • Targeted Therapy
  • Therapy
  • AbbVie Inc.

Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2023 - Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs

  • $ 4995
  • March 2018
  • 148 pages

Do rheumatoid arthritis and lymphoma share risk factors?

  • Clinical Trial
  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • AbbVie Inc.

Global Antibody Drug Conjugates Market – Analysis By Drugs , Pipeline Drugs, Regulations: Opportunities and Forecasts - By Region ; By Country

  • $ 1800
  • March 2017
  • 154 pages

ACCORDING TO LYMPHOMA RESEARCH FOUNDATION THERE WERE AROUND ## PATIENTS SUFFERING FROM HODGKIN' S LYMPHOMA IN US.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • World
  • AbbVie Inc.

Chronic Lymphocytic Leukemia: Opportunity Analysis and Forecasts to 2027

  • $ 10995
  • November 2018
  • 151 pages

ET AL. (2008) ' COMORBID CONDITIONS AND SURVIVAL IN UNSELECTED, NEWLY DIAGNOSED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA', LEUKEMIA AND LYMPHOMA, ##(##), PP. ##-##.

  • Immunotherapy
  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • AbbVie Inc.

PARP Inhibitors in Oncology

  • $ 7995
  • September 2018
  • 116 pages

lymphoma) Orphan Drug Designation (ovarian) Fast Track Designation (ovarian) NCT## NCT## NCT## NCT## NCT## NCT## NCT## NCT## NCT## NCT## NCT## NCT## Phase III Phase II Designations SmallMoleculePARPInhibitors End date:

  • Clinical Trial
  • Targeted Therapy
  • Therapy
  • United States
  • AbbVie Inc.
View report >

Medical Biotechnology Industry in the US - Forecast

  • June 2017
  • 15 pages

Gazyva (Obinutuzumab) Roche 2015 sales: $## million 2022 sales: $##. ## billion CLL; follicular lymphoma ##.

  • Lymphoma
  • Medical Biotechnology
  • United States
  • AbbVie Inc.
  • Pfizer Inc.

Therapy Market in the US November 2019

Therapy Market January 2017

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on